{
  "retracted": false,
  "timestamp": 1548979200000,
  "updates": [
    {
      "timestamp": 1588923684913,
      "identifier": {
        "doi": "10.1136/rmdopen-2018-000692corr1"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1136/rmdopen-2018-000692"
  },
  "publisher": "BMJ",
  "title": "Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors"
}
